Pregabalin is effective against behavioral and electrographic seizures during alcohol withdrawal

Alcohol and Alcoholism

Volumn 41, Issue 4, 2006, Pages 399-406

  Becker, Howard C ^a,b,c   Myrick, Hugh ^a,b,c   Veatch, Lynn M ^a,b,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; GABAPENTIN; PREGABALIN;

ADOLESCENT; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; ELECTRIC POTENTIAL; ELECTROENCEPHALOGRAPHY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

ADMINISTRATION, INHALATION; ALCOHOL WITHDRAWAL SEIZURES; ANIMALS; ANTICONVULSANTS; BEHAVIOR, ANIMAL; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROENCEPHALOGRAPHY; ETHANOL; GAMMA-AMINOBUTYRIC ACID; INJECTIONS, INTRAPERITONEAL; MALE; MICE; MICE, INBRED C3H; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 33745684387     PISSN: 07350414     EISSN: 14643502     Source Type: Journal    
DOI: 10.1093/alcalc/agl029     Document Type: Article

References (57)

1. Andre, V., Rigoulot, M. A., Koning, E. et al. (2003) Long-term pregabalin treatment protects basal cortices and delays the occurrence of spontaneous seizures in the lithium-pilocarpine model in the rat. Epilepsia 44, 893-903.
2. Anton, R. F. and Becker, H. C. (1995) Pharmacology and pathophysiology of alcohol withdrawal. In Handbook of Experimental Pharmacology: The Pharmacology of Alcohol Abuse, Kranzler, H. R. ed., pp. 315-367. Springer-Verlag, Berlin.
3. Arroyo, S., Anhut, H., Kugler, A. R. et al. (2004) Pregabalin add-on treatment: A randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45, 20-27.
4. Ballenger, J. C. and Post, R. M. (1978) Kindling as a model for alcohol withdrawal syndromes. British Journal of Psychiatry 133, 1-14.
5. Becker, H. C. (1994) Positive relationship between the number of prior ethanol withdrawal episodes and the severity of subsequent withdrawal seizures. Psychopharmacology 116, 26-32.
6. Becker, H. C. (1998) Kindling in alcohol withdrawal. Alcohol Health & Research World 22, 25-33.
7. Becker, H. C. (2000) Animal models of alcohol withdrawal. Alcohol Health & Research World 24, 105-113.
8. Becker, H. C. and Hale, R. L. (1993) Repeated episodes of ethanol withdrawal potentiate the severity of subsequent withdrawal seizures: An animal model of alcohol withdrawal 'kindling'. Alcoholism: Clinical and Experimental Research 17, 94-98.
9. Becker, H. C. and Littleton, J. M. (1996) The alcohol withdrawal 'kindling' phenomenon: Clinical and experimental findings. Alcoholism: Clinical and Experimental Research 20, 121A-124A.
10. Becker, H. C. and Veatch, L. M. (2002) Effects of lorazepam. treatment for multiple ethanol withdrawals in mice. Alcoholism: Clinical and Experimental Research 26, 371-380.
11. Becker, H. C., Diaz-Granados, J. L. and Hale, R. L. (1997a) Exacerbation of ethanol withdrawal seizures in mice with a history of multiple withdrawal experience. Pharmacology Biochemistry and Behavior 57, 179-183.
12. Becker, H. C., Diaz-Granados, J. L. and Weathersby, R. T. (1997b) Repeated ethanol withdrawal experience increases the severity and duration of subsequent withdrawal seizures in mice. Alcohol 14, 319-326.
13. Ben-Menachem, E. (2004) Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 45, (Suppl. 6), 13-18.
14. Bialer, M., Johannessen, S. I., Kupferberg, H. J. et al. (2004) Progress report on new antiepileptic drugs: A summary of the Seventh Eilat Conference (EILAT VII). Epilepsy Research 61, 1-48.
15. Brodie, M. J. (2004) Pregabalin as adjunctive therapy for partial seizures. Epilepsia 45 (Suppl. 6), 19-27.
16. Brower, K. J., Aldrich, M. S. and Hall, J. M. (1998) Polysomnographic and subjective sleep predictors of alcoholic relapse. Alcoholism: Clinical and Experimental Research 22, 1864-1871.
17. Bryans, J. S. and Wustrow, D. J. (1999) 3-Substituted GABA analogs with central nervous system activity: A review. Medical Research Reviews 19, 149-177.
18. Chesler, E. J., Ritchie, J., Kokayeff, A. et al. (2003) Genotype-dependence of gabapentin and pregabalin sensitivity: The pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain 106, 325-335.
19. Crabbe, J. and Kosobud, A. (1990) Alcohol withdrawal seizures: Genetic animal models. In Alcohol and Seizures: Basic Mechanisms and Clinical Concepts, Porter, R. J., Mattson, R. H., Cramer, J. A. and Diamond, I. eds, pp. 126-139. F. A. Davis Company, Philadelphia.
20. Cunningham, M. O., Woodhall, G. L., Thompson, S. E. et al. (2004) Dual effects of gabapentin and pregabalin on glutamate release at rat entorhinal synapses in vitro. European Journal of Neuroscience 20, 1566-1576.
21. 3H]-norepinephrine release from rat neocortical slices. Synapse 45, 171-190.
22. Dworkin, R. H., Corbin, A. E., Young, J. P. et al. (2003) Pregabalin for the treatment of postherpetic neuralgia: A randomized, placebo-controlled trial. Neurology 60, 1274-1283.
23. Ellis, R. and Gulick, D. (1991) Calculus: One and Several Variables. Harcourt Brace Jovanovich, San Diego.
24. Fehrenbacher, J. C., Taylor, C. P. and Vasko, M. R. (2003) Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C. Pain 105, 133-141.
25. Feltner, D. E., Crockatt, J. G., Dubovsky, S. J. et al. (2003) A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. Journal of Clinical Psychopharmacology 23, 240-249.
26. Field, M. J., Oles, R. J. and Singh, L. (2001) Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. British Journal of Pharmacology 132, 1-4.
27. +) influx by gabapentin and pregabalin in the human neocortex. Neuropharmacology 42, 229-236.
28. Franklin, K. B. J. and Paxinos, G. (1997) The Mouse Brain in Sterotaxic Coordinates. Academic Press, San Diego, CA.
29. French, J. A., Kugler, A. R., Robbins, J. L. et al. (2003) Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60, 1631-1637.
30. Gillin, J. C., Smith, T. L., Irwin, M. et al. (1990) EEG sleep studies in 'Pure' primary alcoholism during subacute withdrawal: Relationships to normal controls, age, and other clinical variables. Biological Psychiatry 27, 477-488.
31. Griffiths, R. R. (1990) Institute of Medicine: Prevention and Treatment of Alcohol Problems. pp. 268-269. National Academy Press, Washington, DC.
32. Griffiths, R. R. and Sannerud, C. A. (1987) Abuse of a dependence on benzodiazepines and other anxiolytic/sedative drugs. In Psychopharmacology The Third Generation of Progress, Herbert, Y. and Melzer, Y. eds, pp. 1535-1541. Raven Press, New York.
33. Groseclose, C. H., Draughn, R. A., Tyor, W. R. et al. (1998) Longterm intracranial cannula stabilization in mice with light cured resin composites. Journal of Neuroscience Methods 79, 31-36.
34. Guppy, L. J., Crabbe, J. C. and Littleton, J. M. (1995) Time course and genetic variation in the regulation of calcium channel antagonist binding sites in rodent tissues during the induction of ethanol physical dependence and withdrawal. Alcohol and Alcoholism 30, 607-615.
35. Hartings, J. A., Williams, A. J. and Tortella, F. C. (2003) Occurrence of nonconvulsive seizures, periodic epileptiform discharges, and intermittent rhythmic delta activity in rat focal ischemia. Experimental Neurology 179, 139-149.
36. Kubota, T., Fang, J., Meltzer, L. T. et al. (200 1) Pregabalin enhances nonrapid eye movement sleep. Journal of Pharmacology and Experimental Therapeutics 299, 1095-1105.
37. Littleton, J. M., Little, H. J. and Whittington, M. A. (1990) Effects of dihydropyridine calcium channel antagonists in ethanol withdrawal; dose required, stereospecificity and actions of Bay K 8644. Psychopharmacology 100, 387-392.
38. Malcolm, R., Roberts, J. S., Wang, W. et al. (2000) Multiple previous detoxifications are associated with less responsive treatment and heavier drinking during an index outpatient detoxification. Alcohol 22, 159-164.
39. Malcolm, R., Myrick, H., Brady, K. T. et al. (2001) Update on anticonvulsants for the treatment of alcohol withdrawal. American Journal on Addictions 10 (Suppl.), 16-23.
40. Myrick, H. and Anton, R. F. (2000) Clinical management of alcohol withdrawal. CNS Spectrums 5, 22-32.
41. Myrick, H., Brady, K. T. and Malcolm, R. (2001) New developments in the pharmacotherapy of alcohol dependence. American Journal on Addictions 10 (Suppl.), 3-15.
42. Myrick, H., Malcolm, R. and Anton, R. F. (2003) The use of antiepileptics in the treatment of addictive disorders. Primary Psychiatry 10, 59-63.
43. Pande, A. C., Crockatt, J. G., Feltner, D. E. et al. (2003) Pregabalin in generalized anxiety disorder: A placebo-controlled trial. American Journal of Psychiatry 160, 533-540.
44. Pande, A. C., Feltner, D. E., Jefferson, J. W. et al. (2004) Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: A placebo-controlled, multicenter study. Journal of Clinical Psychopharmacology 24, 141-149.
45. Rosenstock, J., Tuchman, M., LaMoreaux, L. et al. (2004) Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 110, 628-638.
46. Sabatowski, R., Galvez, R., Cherry, D. A. et al. (2004) Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: Results of a randomised, placebo-controlled clinical trial. Pain 109, 26-35.
47. Snead, O. C. (1995) Basic mechanisms of generalized absence seizures. Annals of Neurology 37, 146-157.
48. Stahl, S. M. (2004) Mechanism of action of alpha2delta ligands: Voltage sensitive calcium channel (VSCC) modulators. Journal of Clinical Psychiatry 65, 1033-1034.
49. Taylor, C. P. and Vartanian, M. G. (1997) Profile of the anticonvulsant activity of CI-1008 (pregabalin) in animal models. Epilepsia 38 (Suppl. 8), 35.
50. Taylor, C. P., Vartanian, M. G., Andruszkiewicz, R. et al. (1992) 3-Alkyl GABA and 3-alkylglutamic acid analogues: Two new classes of anticonvulsant agents. Epilepsy Research 11, 103-110.
51. Vartanian, M. G., Radulovic, L. L., Kinsora, J. J. et al. (2006) Activity profile of pregabalin in rodent models of epilepsy and ataxia. Epilepsy Research 68, 189-205.
52. Veatch, L. M. and Becker, H. C. (2000) Treatment of multiple ethanol withdrawals with gabapentin: Behavioral and electrographic measures in mice. Society for Neuroscience 26, 802.
53. Veatch, L. M. and Becker, H. C. (2002) Electrographic and behavioral indices of ethanol withdrawal sensitization. Brain Research 946, 272-282.
54. Veatch, L. M. and Gonzalez, L. P. (1997) Nifedipine modifies kindling after chronic ethanol exposure. Alcoholism: Clinical and Experimental Research 21, 5A.
55. Veatch, L. M., Myrick, D. L. and Becker, H. C. (2001) Effects of gabapentin treatment on behavioral and electrographic measures of seizure activity following multiple ethanol withdrawals in mice. Alcoholism: Clinical and Experimental Research 25, 22A.
56. Watson, W. P. and Little, J. J. (1997) Effects of dihydropyridines on the components of the ethanol withdrawal syndrome: Possible evidence for involvement of potassium, as well as calcium? Alcoholism: Clinical and Experimental Research 21, 409-416.
57. Williams, A. J., Tortella, F. C., Lu, X. M. et al. (2004) Antiepileptic drug treatment of nonconvulsive seizures induced by experimental focal brain ischemia. Journal of Pharmacology and Experimental Therapeutics 311, 220-227.